A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 53-59

  Blackburn, Edith ^a   Zona, Stefania ^a   Murphy, Mariana L ^a   Brown, Ian R ^a   Chan, Samuel K W ^a,b   Gullick, William J ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

^b York Teaching Hospital Foundation Trust   (United Kingdom)

Author keywords

Growth Factor Receptor; HER3; Monoclonal antibody; Neuregulin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; NEUREGULIN 1 BETA; SGP 1; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; NEUREGULIN-1; PROTEIN BINDING; RECEPTOR, ERBB-3;

EID: 84863988962     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1908-1     Document Type: Article

References (22)

1. CD Austin AM De Maziere PI Pisacane SM van Dijk C Eigembrot MX Sliwkowski J Klumperman RH Scheller 2004 Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol Biol Cell 15 5268 5282 15385631 10.1091/mbc.E04-07-0591 1:CAS:528:DC%2BD2cXhtVGlsLvP
2. J Baselga SM Swain 2009 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 463 475 19536107 10.1038/nrc2656 1:CAS:528:DC%2BD1MXnsVagtbs%3D
3. MR Campbell D Amin MM Moasser 2010 HER3 comes of age: new insights into its function and role in signalling, tumour biology, and cancer therapy Clin Cancer Res 16 1373 1383 20179223 10.1158/1078-0432.CCR-09-1218 1:CAS:528:DC%2BC3cXisFSisro%3D
4. A Citri KB Skaria Y Yarden 2003 The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp Cell Res 284 54 65 12648465 10.1016/S0014-4827(02)00101-5 1:CAS:528:DC%2BD3sXitVyltrg%3D
5. M Dunn P Sinha R Campbell E Blackburn N Levinson R Rampaul T Bates S Humphreys WJ Gullick 2004 Co-expression of Neuregulins 1, 2, 3, and 4 in human breast cancer J Pathol 203 672 680 15141382 10.1002/path.1561 1:CAS:528:DC%2BD2cXlsVWkurw%3D
6. MA Fabian, et al. 2005 A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 3 329 336 10.1038/nbt1068
7. AW Hamburger 2008 The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies J Mammary Gland Biol Neoplasia 13 225 233 18425425 10.1007/s10911-008-9077-5
8. NLV Hayes E Howard-Cofield WJ Gullick 2004 Green fluorescent protein as a tool to study epidermal growth factor receptor function Cancer Lett 206 129 135 15013518 10.1016/j.canlet.2003.08.030 1:CAS:528:DC%2BD2cXhvFaiu74%3D
9. JT Jones RW Akita MX Sliwkowski 1999 Binding specificities and affinities of egf domains for ErbB receptors FEBS Lett 447 227 231 10214951 10.1016/S0014-5793(99)00283-5 1:CAS:528:DyaK1MXis1ars7w%3D
10. C Knuefermann Y Lu B Liu W Jin K Liang L Wu M Schmidt G Mills J Mendelsohn Z Fan 2003 HER2/PI-3 K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 22 3212 3295 10.1038/sj.onc. 1206394
11. AK Koutras G Fountzilas KT Kalogeras I Starakis G Iconomou HP Kalofonos 2010 The upgraded role of HER3 and HER4 receptors in breast cancer Crit Rev Oncol Hematol 74 73 78 19481955 10.1016/j.critrevonc.2009.04.011
12. B Liu D Ordonez-Ercan Z Fan SM Edgerton X Yang AD Thor 2007 Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells Int J Cancer 120 1874 1882 17266042 10.1002/ijc.22423 1:CAS:528:DC%2BD2sXjsVCqs7c%3D
13. E McIntyre E Blackburn PJ Brown CG Johnson WJ Gullick 2010 The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer Breast Cancer Res Treat 122 105 110 19760033 10.1007/s10549-009-0536-5 1:CAS:528:DC%2BC3cXntlKlsL4%3D
14. AB Motoyama NE Hynes HA Lane 2002 The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res 62 3151 3158 12036928 1:CAS:528: DC%2BD38XksVyqs70%3D
15. SA Prigent WJ Gullick 1994 Identification of c-erbB-3 binding sites for phosphatidylinisitol 3-kinase and SHC using an EGF receptor/c-erbB-3 chimera EMBO J 13 2831 2841 8026468 1:CAS:528:DyaK2cXkslCmur4%3D
16. T Rajkumar WJ Gullick 1994 A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines Br J Cancer 70 459 465 8080731 10.1038/bjc.1994.328 1:CAS:528:DyaK2cXmt1Olsb4%3D
17. B Schoeberl, et al. 2010 An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation Cancer Res 70 2485 2494 20215504 10.1158/0008-5472.CAN-09-3145 1:CAS:528:DC%2BC3cXjtFygtbg%3D
18. NV Sergina M Rausch D Wang J Blair KM Shokat MM Moasser 2007 Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 437 441 17206155 10.1038/nature05474 1:CAS:528:DC%2BD2sXos12msA%3D%3D
19. F Shi SE Telesco R Radhakrishnan MA Lemmon 2010 ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc Natl Acad Sci USA 107 7692 7697 20351256 10.1073/pnas.1002753107 1:CAS:528: DC%2BC3cXls1amsbc%3D
20. E Tzahar H Waterman X Chen G Levkowitz D Karunagaran S Lavi BJ Ratzkin Y Yarden 1996 A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/Neuregulin and epidermal growth factor Mol Cell Biol 16 5276 5287 8816440 1:CAS:528:DyaK28XlvFamt70%3D
21. EH Van der Horst M Murgia M Treder A Ullrich 2005 Anti-HER-3 MAbs inhibits HER-3-mediated signalling in breast cancer cell lines resistant to anti-HER-2 antibodies Int J Cancer 115 519 527 15704104 10.1002/ijc.20867
22. BB Zhou, et al. 2006 Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer Cancer Cell 10 39 50 16843264 10.1016/j.ccr.2006.05.024 1:CAS:528:DC%2BD28XnsFOhs78%3D